{"nctId":"NCT01265550","briefTitle":"A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors","startDateStruct":{"date":"2012-08-13","type":"ACTUAL"},"conditions":["GERD"],"count":366,"armGroups":[{"label":"Medical Treatment Group","type":"OTHER","interventionNames":["Drug: baclofen","Drug: Desipramine"]},{"label":"Surgical Treatment Group","type":"OTHER","interventionNames":["Device: Nissen fundoplication"]},{"label":"Placebo Medical Treatment Group","type":"OTHER","interventionNames":["Drug: baclofen","Drug: Desipramine"]}],"interventions":[{"name":"Nissen fundoplication","otherNames":[]},{"name":"baclofen","otherNames":[]},{"name":"Desipramine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18-70 years\n* History of heartburn (defined as a burning sensation in the retrosternal area of the chest) that is refractory to antisecretory medications\n* Initial GERD-HRQL:\n\n  * Total score must be at least 6 and at least one of the six heartburn questions must be scored at least 2\n* GERD-HRQL after two weeks of treatment with omeprazole:\n\n  * Total score must be \\>50% of the initial GERD-HRQL score and at least one of the six heartburn questions must be scored at least 2\n* Either or both of the following by baseline esophageal pH/multichannel intraluminal impedance (MII) monitoring in patients on omeprazole 20 mg two times a day (BID):\n\n  * Positive symptom association probability (SAP) (\\>95%) for acid reflux, non-acid reflux or all reflux.\n  * Abnormal acid reflux (esophageal pH\\<4 for at least 4.2% of the 24-hour monitoring period)\n\nExclusion Criteria:\n\n* Patients who do not have heartburn, defined as a burning sensation in the chest\n* Patients unwilling or unable to provide informed consent\n* Pregnancy or women unwilling to use effective contraception\n* Age \\<18 or \\>70 years\n* History of surgery on the stomach or esophagus\n* History of seizure disorder\n* History of heart block\n* Allergy to or previous inability to tolerate study medications (omeprazole, baclofen, desipramine)\n* Esophageal varices\n* Cirrhosis\n* Co-morbidity of sufficient severity to preclude elective surgery (e.g. pulmonary, cardiac, renal, liver disease)\n* History of disorders that can cause medically-refractory \"GERD symptoms\" (eosinophilic esophagitis, neoplasms of the upper gastrointestinal tract, gastroparesis, achalasia)\n* Myocardial infarction within the past 6 months\n* History of schizophrenia\n* Current use of clopidogrel\n* Patients who have a contraindication to omeprazole or baclofen or who require therapy with a medication that has a clinically important drug interaction with omeprazole or baclofen.\n* Patients who, in the judgment of the PI, are not suitable candidates for therapy with a study medication (omeprazole, baclofen, desipramine)\n* Initial GERD-HRQL score: Total score \\<6 and/or all heartburn scores \\<2\n* Inability to tolerate omeprazole during the 2-week treatment phase (before randomization)\n* GERD-HRQL after two weeks of treatment with omeprazole: Total score less than or equal to 50% of initial GERD-HRQL score and/or all heartburn scores \\<2\n* Laboratory abnormalities including:\n\n  * Platelet count \\<100,000\n  * international normalized ratio (INR) \\>1.5 (off anticoagulants)\n  * Serum creatinine \\>2.0 mg per deciliter\n* Endoscopic abnormalities including:\n\n  * Los Angeles Classification of Oesophagitis (LA grade) C or D reflux esophagitis\n  * Active ulceration of the esophagus that is not due to reflux esophagitis\n  * Candida esophagitis\n  * Esophageal varices\n  * Active ulceration of the stomach and/or duodenum\n  * Neoplasm of the esophagus, stomach or duodenum\n  * Gastric outlet obstruction\n  * Eosinophilic esophagitis at least (15 eosinophils per high power field in any esophageal biopsy specimen)\n* Manometric abnormalities including:\n\n  * Achalasia\n  * Complete aperistalsis\n* Negative SAP ( 95%) for acid reflux, non-acid reflux and all reflux on baseline combined esophageal pH/MII monitoring and normal acid reflux (esophageal pH\\<4 for \\<4.2% of the 24-hour monitoring period)\n* Study surgeon identifies a contraindication to laparoscopic Nissen fundoplication\n* Morbid obesity (BMI at least 40)\n* Large paraesophageal hernia","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months","description":"Success; â‰¥50% improvement in the baseline GERD-HRQL score at 12 months.\n\nFailure; \\<50% improvement in the baseline GERD-HRQL score at 12 months or:\n\n1. For patients randomized to Surgical Treatment: a.\\<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit.\n2. For patients randomized to Active Medical or Placebo Medical Treatment:\n\n   a.inability to tolerate both study medications or b.For patients treated with desipramine, i.\\<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.\\<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Esophageal Ulceration.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Reflux Esophagus.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Eosinophilic Esophagitis","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Candida Esophagitis.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Gastric Outlet Obstruction","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Achalasia","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Aperistalsis","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Distal Esophageal Spasm","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Nutcracker Esophagus","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Ineffective Esophageal Motility","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Rapid Contraction","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Hypertensive Peristalsis","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Jackhammer Esophagus","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Weak Peristalsis I","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Weak Peristalsis II","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Anxiety and/or Depression","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Functional Heartburn","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Functional Dysphagia","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Globus","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Belching Disorders","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Chronic Idiopathic Nausea","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Functional Vomiting","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Cyclic Vomiting Syndrome","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Irritable Bowel Syndrome","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Functional Bloating","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Functional Diarrhea","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Unspecified Functional Bowel Disorder","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Enrolled Participants With Functional Gallbladder Disorder","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Anxiety and/or Depression.","description":"Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Functional Heartburn","description":"Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin","description":"Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Functional Dysphagia","description":"Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Globus","description":"Presence of globus as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Belching Disorders","description":"Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Chronic Idiopathic Nausea","description":"Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Functional Vomiting","description":"Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Cyclic Vomiting Syndrome","description":"Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Irritable Bowel Syndrome","description":"Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Functional Bloating","description":"Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Functional Diarrhea","description":"Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Unspecified Functional Bowel Disorder","description":"Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Participants With Functional Gallbladder Disorder","description":"Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":25},"commonTop":["Diarrhoea","Dyspepsia","Vomiting","Dysphagia","Constipation"]}}}